JP1302 NEW
| Price | $38 | $89 | $133 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-07-16 |
Product Details
| Product Name: JP1302 | CAS No.: 80259-18-3 |
| Purity: 99.96% | Supply Ability: 10g |
| Release date: 2025/07/16 |
Product Introduction
Bioactivity
| Name | JP1302 |
| Description | JP1302 is a selective α2C adrenoceptor antagonist with a Kb value of 16 nM and a Ki of 28 nM for human α2C receptors.JP1302 has antidepressant activity, disrupts the FACT complex and degrades histone H1.JP1302 has been used in the study of neuropsychiatric disorders, acute renal failure, and renal injury. |
| In vitro | JP1302 exhibits approximately a 100-fold greater affinity compared to α2A or α2B.[1] |
| In vivo | JP1302 (5 μmol/kg; once; Sprague-Dawley rats) is capable of complete reversal of the impairment in PPI induced in Sprague-Dawley rats by the psychotomimetic NMDA receptor antagonist, phencyclidine, and similar results are found in Wistar rats.[1] JP1302 (1-10 μmol/kg) decreases immobility time in the FST to a level similar to that seen with 10-30?μmol/kg of the antidepressant Desipramine.[1] JP1302 (3 mg/kg; IV, pre-treatment: administered 5 min before the induction of ischemia, post-treatment: injected 45 min after the initiation of reperfusion; once; Male Sprague Dawley rats ) significantly ameliorated renal dysfunction in the rats at 24 h after reperfusion. post-ischemic administration of JP-1302 significantly ameliorated renal dysfunction, and histological damage and reduced apoptotic cells and pro-inflammatory cytokine mRNA expression.[3] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 36.85 mg/mL (100.01 mM), Sonication is recommended. H2O : insoluble |
| Keywords | α2C-adrenergic receptor | JP-1302 | JP1302 | JP 1302 dihydrochloride | JP 1302 | AdrenergicReceptor | Adrenergic Receptor |
| Inhibitors Related | Olanzapine | Mirtazapine | Octopamine hydrochloride | Gemfibrozil | Buflomedil hydrochloride | Dexmedetomidine hydrochloride | Phenylephrine hydrochloride | Amitriptyline hydrochloride | Isoprenaline hydrochloride | Trazodone hydrochloride | Mianserin hydrochloride | Doxepin hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | Endocrinology-Hormone Compound Library | Anti-Cardiovascular Disease Compound Library | Bioactive Compounds Library Max | Adrenergic Receptor-Targeted Compound Library | GPCR Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $38.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-19 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY